207 related articles for article (PubMed ID: 27635042)
1. Molecular or Metabolic Reprograming: What Triggers Tumor Subtypes?
Eason K; Sadanandam A
Cancer Res; 2016 Sep; 76(18):5195-200. PubMed ID: 27635042
[TBL] [Abstract][Full Text] [Related]
2. Nature and Nurture: What Determines Tumor Metabolic Phenotypes?
Mayers JR; Vander Heiden MG
Cancer Res; 2017 Jun; 77(12):3131-3134. PubMed ID: 28584183
[TBL] [Abstract][Full Text] [Related]
3. The matrix environmental and cell mechanical properties regulate cell migration and contribute to the invasive phenotype of cancer cells.
Mierke CT
Rep Prog Phys; 2019 Jun; 82(6):064602. PubMed ID: 30947151
[TBL] [Abstract][Full Text] [Related]
4. Targeting cancer's metabolic co-dependencies: A landscape shaped by genotype and tissue context.
Bi J; Wu S; Zhang W; Mischel PS
Biochim Biophys Acta Rev Cancer; 2018 Aug; 1870(1):76-87. PubMed ID: 29775654
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms and clinical implications of tumor heterogeneity and convergence on recurrent phenotypes.
McQuerry JA; Chang JT; Bowtell DDL; Cohen A; Bild AH
J Mol Med (Berl); 2017 Nov; 95(11):1167-1178. PubMed ID: 28871446
[TBL] [Abstract][Full Text] [Related]
6. Developmental origins and oncogenic pathways in malignant brain tumors.
Lu QR; Qian L; Zhou X
Wiley Interdiscip Rev Dev Biol; 2019 Jul; 8(4):e342. PubMed ID: 30945456
[TBL] [Abstract][Full Text] [Related]
7. Pancreatic Cancer Heterogeneity Can Be Explained Beyond the Genome.
Juiz NA; Iovanna J; Dusetti N
Front Oncol; 2019; 9():246. PubMed ID: 31024848
[TBL] [Abstract][Full Text] [Related]
8. Intra-tumor heterogeneity from a cancer stem cell perspective.
Prasetyanti PR; Medema JP
Mol Cancer; 2017 Feb; 16(1):41. PubMed ID: 28209166
[TBL] [Abstract][Full Text] [Related]
9. Cancer stem cells (CSCs): metabolic strategies for their identification and eradication.
De Francesco EM; Sotgia F; Lisanti MP
Biochem J; 2018 May; 475(9):1611-1634. PubMed ID: 29743249
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms Governing Metabolic Heterogeneity in Breast Cancer and Other Tumors.
Patra S; Elahi N; Armorer A; Arunachalam S; Omala J; Hamid I; Ashton AW; Joyce D; Jiao X; Pestell RG
Front Oncol; 2021; 11():700629. PubMed ID: 34631530
[TBL] [Abstract][Full Text] [Related]
11. Claudin-low-like mouse mammary tumors show distinct transcriptomic patterns uncoupled from genomic drivers.
Fougner C; Bergholtz H; Kuiper R; Norum JH; Sørlie T
Breast Cancer Res; 2019 Jul; 21(1):85. PubMed ID: 31366361
[TBL] [Abstract][Full Text] [Related]
12. Not Everyone Fits the Mold: Intratumor and Intertumor Heterogeneity and Innovative Cancer Drug Design and Development.
Dzobo K; Senthebane DA; Thomford NE; Rowe A; Dandara C; Parker MI
OMICS; 2018 Jan; 22(1):17-34. PubMed ID: 29356626
[TBL] [Abstract][Full Text] [Related]
13. Tumor heterogeneity: does it matter?
Turnquist C; Watson RA; Protheroe A; Verrill C; Sivakumar S
Expert Rev Anticancer Ther; 2019 Oct; 19(10):857-867. PubMed ID: 31510810
[No Abstract] [Full Text] [Related]
14. Single cell genomics reveals activation signatures of endogenous SCAR's networks in aneuploid human embryos and clinically intractable malignant tumors.
Glinsky GV
Cancer Lett; 2016 Oct; 381(1):176-93. PubMed ID: 27497790
[TBL] [Abstract][Full Text] [Related]
15. Molecular subtypes in cancers of the gastrointestinal tract.
Bijlsma MF; Sadanandam A; Tan P; Vermeulen L
Nat Rev Gastroenterol Hepatol; 2017 Jun; 14(6):333-342. PubMed ID: 28400627
[TBL] [Abstract][Full Text] [Related]
16. Intra-tumor heterogeneity in breast cancer has limited impact on transcriptomic-based molecular profiling.
Karthik GM; Rantalainen M; Stålhammar G; Lövrot J; Ullah I; Alkodsi A; Ma R; Wedlund L; Lindberg J; Frisell J; Bergh J; Hartman J
BMC Cancer; 2017 Nov; 17(1):802. PubMed ID: 29187174
[TBL] [Abstract][Full Text] [Related]
17. Pan-cancer analysis of tumor metabolic landscape associated with genomic alterations.
Choi H; Na KJ
Mol Cancer; 2018 Oct; 17(1):150. PubMed ID: 30333042
[TBL] [Abstract][Full Text] [Related]
18. Metabolic reprogramming of carcinoma-associated fibroblasts and its impact on metabolic heterogeneity of tumors.
Wu D; Zhuo L; Wang X
Semin Cell Dev Biol; 2017 Apr; 64():125-131. PubMed ID: 27833036
[TBL] [Abstract][Full Text] [Related]
19. Next-generation clinical trials: Novel strategies to address the challenge of tumor molecular heterogeneity.
Catenacci DV
Mol Oncol; 2015 May; 9(5):967-96. PubMed ID: 25557400
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic heterogeneity in cancer.
Guo M; Peng Y; Gao A; Du C; Herman JG
Biomark Res; 2019; 7():23. PubMed ID: 31695915
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
